Related Experiment Video

Updated: Mar 1, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K

Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle

Luc E Gosselin1, Jacqueline E Williams

  • 1Department of Exercise and Nutrition Sciences, 405 Kimball Tower, University at Buffalo, Buffalo, New York 14214, USA. gosselin@buffalo.edu

Muscle & Nerve
|February 28, 2006
PubMed

Insights

Pentoxifylline (PTX) did not reduce fibrosis in mdx mouse diaphragm muscle. This study found no improvement in muscle function or collagen levels, suggesting PTX is not effective for treating muscular dystrophy fibrosis.

Area of Science:

  • Muscle physiology and pathology
  • Pharmacological interventions for genetic disorders

Background:

  • Fibrosis is a key pathological feature in Duchenne muscular dystrophy (DMD) and mdx mouse models.
  • Diaphragm muscle is significantly affected by fibrosis in these conditions.

Purpose of the Study:

  • To investigate the antifibrotic effects of pentoxifylline (PTX) in the diaphragm muscle of mdx mice.
  • To assess the impact of PTX on fibrosis, collagen levels, and muscle function.

Main Methods:

  • MDX mice were treated with PTX (16 mg/kg/day) for 4 weeks.
  • Diaphragm muscle fibrosis was evaluated by measuring hydroxyproline concentration and collagen type I and III mRNA levels.
  • In vitro contractile function of the diaphragm muscle was assessed.

Main Results:

  • PTX treatment did not significantly alter diaphragm muscle hydroxyproline concentration.
  • Levels of type I and III collagen mRNA and TGF-beta1 mRNA remained unaffected by PTX.
  • In vitro contractile function of the diaphragm muscle was not improved by PTX treatment.

Conclusions:

  • Pentoxifylline (PTX) does not attenuate fibrosis in the diaphragm muscle of mdx mice.
  • The drug did not impact key markers of fibrosis or muscle function.
  • These findings do not support the use of PTX as an antifibrotic therapy for muscular dystrophy.

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

34.0K
Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

34.0K

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
588